Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on February 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Ultragenyx Pharmaceutical Stock Down 2.8%

Shares of RARE opened at $22.21 on Thursday. The business has a fifty day moving average of $23.08 and a 200 day moving average of $28.93. The company has a market cap of $2.15 billion, a PE ratio of -3.80 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. During the same quarter last year, the firm earned ($1.39) EPS. The company’s revenue was up 25.5% on a year-over-year basis. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 1,632 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $37,209.60. Following the transaction, the chief accounting officer owned 48,670 shares in the company, valued at approximately $1,109,676. This trade represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Eric Crombez sold 7,029 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $160,261.20. Following the completion of the sale, the executive vice president owned 76,301 shares of the company’s stock, valued at $1,739,662.80. The trade was a 8.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 104,958 shares of company stock worth $2,394,858 over the last quarter. Insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Robert W. Baird cut their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Guggenheim dropped their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Wedbush reaffirmed a “neutral” rating and set a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Finally, Leerink Partners reduced their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Sixteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Company presentation transcripts from two healthcare conferences (Leerink and Barclays) were posted this week; these provide management remarks and program updates but contain no new regulatory rulings or approvals that would materially change near‑term outlook. Ultragenyx Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Additional management remarks from the Barclays 28th Annual Global Healthcare Conference were released as a transcript; useful for modelers of pipeline timing/revenue but not a catalyst that offsets current legal headlines. Ultragenyx Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Negative Sentiment: A new class action filing was announced and a plaintiff‑recruitment notice from Bronstein, Gewirtz & Grossman urges investors to act, signaling formal litigation risk that can pressure the stock. Bronstein, Gewirtz & Grossman Urges Ultragenyx Investors to Act
• Negative Sentiment: Multiple plaintiff firms (Faruqi & Faruqi; Levi & Korsinsky; Kahn Swick & Foti; Rosen; Pomerantz; The Gross Law Firm) have issued reminders/investor alerts about the April 6, 2026 lead‑plaintiff deadline — this concentrated outreach increases publicity about potential liability and can prompt selling or keep buyers sidelined. Faruqi & Faruqi Reminder
• Negative Sentiment: Levi & Korsinsky specifically names the CEO and CMO as potential “control person” defendants, which may heighten perceived executive personal liability and prolong headline risk. Levi & Korsinsky Control Person Alert
• Negative Sentiment: Other firms (Kahn Swick & Foti; Rosen; Pomerantz; The Gross Law Firm) are actively soliciting investors for lead‑plaintiff roles or counsel, sustaining media coverage and investor concern about potential damages, discovery, and distraction from operations. Kahn Swick & Foti Notice

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in the stock. Assetmark Inc. increased its position in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical in the third quarter worth approximately $39,000. Elevation Point Wealth Partners LLC bought a new position in Ultragenyx Pharmaceutical in the second quarter worth approximately $55,000. Finally, Smartleaf Asset Management LLC increased its holdings in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.